Guardant Health, Inc. Common Stock (GH) — Analysis Summary
Guardant Health, Inc. Common Stock (GH) has a market cap of $22.61B with year-over-year revenue growth of +32.9%. Net margin stands at -42.4%. The stock trades at a P/E ratio of -49.9.
Key Takeaways
- Revenue changed +32.9% year-over-year
- Net margin of -42.4%
- P/E ratio of -49.9
Compared to other companies in the SERVICES-MEDICAL LABORATORIES sector, GH posted revenue growth of +32.9% and trades at a P/E of -49.9.
Guardant Health, Inc. Common Stock (GH)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -97.6x — earnings do not cover interest payments
Shareholder equity is negative, which can signal balance-sheet stress.
Operating margin at -39.7% — material operating losses
Net margin at -38.3% — significant losses
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Sector
SERVICES-MEDICAL LABORATORIES
Employees
2,506
Headquarters
PALO ALTO, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.